Multiple endocrine neoplasia type 2 future or investigational therapies: Difference between revisions
No edit summary |
(Mahshid) |
||
Line 53: | Line 53: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Endocrinology]] | |||
[[Category:Surgery]] |
Latest revision as of 02:46, 27 November 2017
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 future or investigational therapies On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 future or investigational therapies |
FDA on Multiple endocrine neoplasia type 2 future or investigational therapies |
CDC on Multiple endocrine neoplasia type 2 future or investigational therapies |
Multiple endocrine neoplasia type 2 future or investigational therapies in the news |
Blogs on Multiple endocrine neoplasia type 2 future or investigational therapies |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Future or investigational therapies of multiple endocrine neoplasia type 2 include treatment with axitinib, gefitinib, imatinib, motesanib, sorafenib, sunitinib, vandetanib and XL184.
Future or investigational therapies
Further studies on the molecular pathways of c-RET gene and its protein will help to design novel and more individualized therapeutic modalities based on genetic information. In fact, although the knowledge about mechanisms of tumor development in patients with multiple endocrine neoplasia type 2 has grown tremendously, much work lies ahead. The final goal is to offer patients with c-RET germline mutations an optimal cancer prevention and treatment program. Table below list the major drugs that are being investigated for the treatment of multiple endocrine neoplasia type 2.
Drug | Target molecule |
---|---|
Axitinib | VEGFR, PDGFR beta, C. Kit |
Gefitinib | EGFR |
Imatinib | VEGFR, RET, BCR-ABL |
Motesanib | VEGFR, RET, PDGFR beta, C. Kit |
Sorafenib | VEGFR, RET, RET/PTC, BRAF, PDGFR beta, C. Kit |
Sunitinib | VEGFR, RET, RET/PTC, PDGFR beta |
Vandetanib | VEGFR, RET, RET/PTC, EGFR |
XL184 | VEGFR, RET, PDGFR beta |
Adapted from C. Romei, E. Pardi, F. Cetani, and R. Elisei Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2, Journal of Oncology, vol. 2012, Article ID 705036, 15 pages, 2012. doi:10.1155/2012/705036[1] |
References
- ↑ Romei C, Pardi E, Cetani F, Elisei R (2012). "Genetic and clinical features of multiple endocrine neoplasia types 1 and 2". J Oncol. 2012: 705036. doi:10.1155/2012/705036. PMC 3503399. PMID 23209466.